Skip to main content
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Current Drug Targets-CNS & Neurological Disorders is now published as CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders).

Publisher: Bentham Science Publishers

Volume 4, Number 3, 2005

Book review

Favourites:
ADD

Review article

The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimer's Disease: Therapeutic Implications
pp. 223-233(11)
Authors: Rozemuller, Annemieke J.M.; van Gool, Willem A; Eikelenboom, Piet

Favourites:
ADD

Amyloid Associated Proteins in Alzheimer's and Prion Disease
pp. 235-248(14)
Authors: Veerhuis, R.; Boshuizen, R. S.; Familian, A.

Favourites:
ADD

Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer's Disease
pp. 249-266(18)
Authors: Lue, L- F.; Yan, S. D.; Stern, D. M.; Walker, D. G.

Favourites:
ADD
Favourites:
ADD

Protein Quality Control in Alzheimer's Disease: A Fatal Saviour
pp. 283-292(10)
Authors: Scheper, W.; Hol, E. M.

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content